NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
31/03/2026
Voltar para busca
Dado oficial do USPTO
CAPSIDA BIOTHERAPEUTICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
CAPSIDA BIOTHERAPEUTICS
ST13
US500000090046614Classe
1, 5, 42
Pedido
90046614
Registro
8196323
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
63
Atualização mais recente
31/03/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42
Data de depósito
10/07/2020
Data de registro
31/03/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
31/03/2026
Última transação
31/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
05/07/2024
Primeiro uso no comércio
05/07/2024
Código do desenho
4
Tipo de titular
03
Localização do titular
Thousand Oaks, CA, US
Examinador
LAPTER, ALAIN J
Unidade examinadora
L50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
CAPSIDA BIOTHERAPEUTICS, INC.
Capsida, Inc.
Representantes
Holly Pranger PRANGER LAW PC
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical and biochemical products for use in gene delivery technologynucleic acidsincluding coding and non-coding deoxyribonucleic acidsplasmidsvectorspromotorsenhancers and other regulatory sequences; Chemical and biochemical products for use in gene delivery technology namelynucleic acidsincluding coding and non-coding deoxyribonucleic acidsvectorspromotorsenhancers and other regulatory sequences for development of therapeutics and the treatment of cardiovascularcentral nervous systemneurologicalperipheral nervous system diseases and disorders; Chemical and biochemical products for use in gene delivery technology namelynucleic acidsincluding plasmids for development of therapeutics and the treatment of central nervous systemneurologicalperipheral nervous system diseases and disorders
Classe 5
Pharmaceutical preparations for use in gene therapy; pharmaceutical preparations for use in gene delivery technology for use in the treatment of central nervous systemneurologicalperipheral nervous system diseases and disorders; pharmaceutical preparations for use in the treatment of gene therapy treatable diseases for use in the treatment of central nervous systemneurologicalperipheral nervous system diseases and disorders; gene therapy and prophylaxis productsgene transferregulationmodulation and delivery pharmaceutical preparations for the treatment of genetic diseases and disorders; pharmaceutical preparations for the treatment of disorders of the central nervous system; pharmaceutical preparations that facilitate administration of other pharmaceutical preparations into the brain for enhanced treatment of disorders of the central nervous systemin the nature of drug delivery agents consisting of viral capsids that facilitate the delivery of the preparations; pre-filled vials containing pharmaceutical preparations for the treatment of central nervous systemneurologicalperipheral nervous system diseases and disorders and complications associated therewith
Classe 42
Pharmaceutical research and development in the field of gene therapy; development of pharmaceutical preparations for use in gene therapy and gene delivery technology; development of products being genetic therapies; scientific research in the field of genetic engineeringbiotechnology research servicesresearch and development of new products in the field of gene therapeutics and research tools; research and development in the biotechnology field; scientific and medical research and development in the field of cardiovascularcentral nervous systemneurologicalophthalmologicperipheral nervous system diseases and disorders and complications associated therewith; scientific research and product development services for others in the pharmaceuticalbiotechnologymedical fields; testinginspectionresearchdevelopment of pharmaceutical preparations for gene therapy and gene delivery technology; biomedical research and developmentscientific research and developmentpharmaceutical research and development and product development services in the fields of genome editinggene editinggenome engineeringgene modulationgenetic diseasesgene therapycell therapy; product development in the fields of genetic therapiesgene delivery technologieseffectors to regulatemodulatecharacterize disease states; biomedical research in the field of gene therapy design and delivery; gene therapy design and product delivery development of biochemical assays; biomedical research and developmentscientific research and developmentpharmaceutical research and development and product development in the fields of cardiovascularcentral nervous systemneurologicalophthalmologicperipheral nervous system diseases and disorders; medical servicesscientific research in the fields of genetic engineering and gene therapy services; medical servicesscientific research in the nature of gene therapy design and delivery services in the field of genetic diseases and disorders
Publicações
Histórico de despachos e eventos da marca no USPTO.
63 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
31/03/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
10/03/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
10/03/2026
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/03/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
06/03/2026
EX5G
SOU EXTENSION 5 GRANTED
06/03/2026
IUAF
USE AMENDMENT FILED
03/10/2025
EXT5
SOU EXTENSION 5 FILED
03/10/2025
EISU
TEAS STATEMENT OF USE RECEIVED
03/10/2025
EEXT
SOU TEAS EXTENSION RECEIVED
03/10/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
29/03/2025
EX4G
SOU EXTENSION 4 GRANTED
29/03/2025
EXT4
SOU EXTENSION 4 FILED
28/03/2025
EEXT
SOU TEAS EXTENSION RECEIVED
28/03/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/10/2024
EX3G
SOU EXTENSION 3 GRANTED
01/10/2024
EXT3
SOU EXTENSION 3 FILED
01/10/2024
EEXT
SOU TEAS EXTENSION RECEIVED
01/10/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/03/2024
EX2G
SOU EXTENSION 2 GRANTED
04/03/2024
EXT2
SOU EXTENSION 2 FILED
04/03/2024
EEXT
SOU TEAS EXTENSION RECEIVED
04/03/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
29/09/2023
EX1G
SOU EXTENSION 1 GRANTED
27/09/2023
EXT1
SOU EXTENSION 1 FILED
27/09/2023
EEXT
SOU TEAS EXTENSION RECEIVED
27/09/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/04/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/02/2023
PUBO
PUBLISHED FOR OPPOSITION
07/02/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/01/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/01/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/12/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/12/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/12/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
23/06/2022
GNRT
NON-FINAL ACTION E-MAILED
23/06/2022
CNRT
NON-FINAL ACTION WRITTEN
23/06/2022
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
21/06/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
16/03/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
16/03/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
16/03/2022
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
01/12/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
01/06/2021
GNSL
LETTER OF SUSPENSION E-MAILED
01/06/2021
CNSL
SUSPENSION LETTER WRITTEN
01/06/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
01/06/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/06/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
01/06/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/06/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
28/05/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
27/05/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
27/05/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/12/2020
GNRT
NON-FINAL ACTION E-MAILED
04/12/2020
CNRT
NON-FINAL ACTION WRITTEN
04/12/2020
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
04/11/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
24/10/2020
GNRT
NON-FINAL ACTION E-MAILED
24/10/2020
CNRT
NON-FINAL ACTION WRITTEN
24/10/2020
DOCK
ASSIGNED TO EXAMINER
21/10/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/08/2020
NWAP
NEW APPLICATION ENTERED
14/07/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CAPSIDA BIOTHERAPEUTICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.